Astrazeneca PLC – Consensus Indicates Potential 26.2% Upside
Astrazeneca PLC with ticker code (AZN) now have 4 analysts covering the stock. The analyst consensus points to a rating of ''Buy''. The range between the high target price and low target price is between 80 and 58.5 and has a mean target at 73.38. With the stocks previous close at 58.14 this would indicate that there is a potential upside of 26.2%. The 50 day MA is 64.82 and the 200 day MA is 62.64. The company has a market cap of $181,168m. Company Website: https:||www.astrazeneca.com [stock_market_widget type="chart" template="basic" color="green" assets="AZN" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $228,656m based on the market concensus. AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta|Brilique, Bydureon|Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga|Forxiga, Komboglyze|Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo|Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp|Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza|Eklira|Bretaris for respiratory and immunology; and Andexxa|Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases.
Astrazeneca PLC – Consensus Indicates Potential 26.2% Upside
Astrazeneca PLC with ticker code (AZN) now have 4 analysts covering the stock. The analyst consensus points to a rating of ''Buy''. The range between the high target price and low target price is between 80 and 58.5 and has a mean target at 73.38. With the stocks previous close at 58.14 this would indicate that there is a potential upside of 26.2%. The 50 day MA is 64.82 and the 200 day MA is 62.64. The company has a market cap of $181,168m. Company Website: https:||www.astrazeneca.com [stock_market_widget type="chart" template="basic" color="green" assets="AZN" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $228,656m based on the market concensus. AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta|Brilique, Bydureon|Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga|Forxiga, Komboglyze|Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo|Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp|Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza|Eklira|Bretaris for respiratory and immunology; and Andexxa|Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases.